Sensus Healthcare, Inc. manufactures, distributes, and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sculptura product, a proprietary modulated robotic brachytherapy oncology therapy system that uses patented Beam Sculpting capabilities to treat various cancers during surgery; and Sentinel service program, which offers its customers protection for their systems. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons, eye shields, and disposable applicator tips, which are used to treat various sized lesions and various areas of the body. Sensus Healthcare, Inc. was incorporated in 2010 and is headquartered in Boca Raton, Florida.
IPO Year: 2016
Exchange: NASDAQ
Website: sensushealthcare.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
11/15/2024 | $12.00 → $14.00 | Buy | Maxim Group |
3/3/2022 | $12.00 → $13.00 | Buy | HC Wainwright & Co. |
2/14/2022 | $10.00 → $12.00 | Buy | HC Wainwright & Co. |
12/2/2021 | $9.00 → $10.00 | Buy | HC Wainwright & Co. |
11/5/2021 | $7.00 → $9.00 | Buy | HC Wainwright & Co. |
8/6/2021 | $6.00 → $7.00 | Buy | HC Wainwright & Co. |
This revised news release replaces the one issued on November 14, 2024, contains several non-financial changes throughout and removes the name of and references to a new customer, at the customer's request. The agreement with the new customer remains in effect. Revenues of $8.8 million compare with $3.9 million in the prior-year quarter, adjusted EBITDA (a non-GAAP measure) of $1.6 million compares with negative $1.7 million a year ago Expects to have more than 50 IG-SRT Systems signed under the Fair Deal Agreement recurring-revenue program by the end of the year BOCA RATON, Fla, Nov. 17, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializin
Revenues of $8.8 million compare with $3.9 million in the prior-year quarter, adjusted EBITDA (a non-GAAP measure) of $1.6 million compares with negative $1.7 million a year agoSigned a Fair Deal Agreement with Platinum Dermatology, a leading dermatology network with 130 clinics across the U.S. Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces financial results for the three and nine months ended September 30, 2
BOCA RATON, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, November 14, 2024 at 4:30 p.m. Eastern time to discuss the financial results for the third quarter of 2024. In addition, management will provide a business update and a discussion on recent and upcoming milestones. Participants are encouraged to pre-register for the conference call using this link. Upon registration participants will receive a unique dial-in number that will permit them to bypass
BOCA RATON, Fla., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces it has shipped an SRT system to Providence Swedish Hospital in Seattle. This sale represents the Company's latest success in generating interest in superficial radiotherapy (SRT) from community hospital oncology departments. Christopher Loiselle, M.D., Medical Director of Radiation Oncology at Swedish Cancer Institute at Providence Swedish, said, "Sensus' SRT system is a state-of-the-art system for optimal tre
Revenues of $9.2 million compares with $4.5 million in the prior-year quarter, adjusted EBITDA (a non-GAAP measure) of $2.1 million compares with negative $1.0 million a year ago"Fair Deal Agreement" recurring revenue program gaining momentum with 15 agreements signed to date Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces financial results for the three and six months ended June 30, 2024. Highlights from the
BOCA RATON, Fla. , Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, reminds investors that management will hold a conference call on Thursday, August 8, 2024 at 4:30 p.m. Eastern time to discuss the financial results for the second quarter of 2024. In addition, management will provide a business update and a discussion on recent and upcoming milestones. Participants are encouraged to pre-register for the conference call using this link. Upon registration participants will receive a unique dial in number that will permit them to
BOCA RATON, Fla., July 25, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, August 8, 2024 at 4:30 p.m. Eastern time to discuss the financial results for the second quarter of 2024. In addition, management will provide a business update and a discussion on recent and upcoming milestones. Participants are encouraged to pre-register for the conference call using this link. Upon registration participants will receive a unique dial in number that will permit them to bypass the
Revenues of $10.7 million, compared with $3.4 million in the prior-year quarter; Adjusted EBITDA (a non-GAAP measure) of $3.0 million, compared with negative $2.7 million in the prior-year quarterLaunched the "Fair Deal Agreement" recurring revenue program to provide an equipment placement option and complement the fair market value lease program for SRT systems Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces financ
First veterinary commercial sale of the SRT-100 outside the U.S. BOCA RATON, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces the sale of an SRT-100 system to Chavat Da'at, the Veterinary Specialist Referral Center Knowledge Farm at Beit Verl College in Tel Aviv, to provide a gentler radiotherapy option to treat tumors in dogs and cats. This is the first commercial sale of the SRT-100 for veterinary use outside the U.S. Veterinary Specialist Referral Center Knowledge Farm was establ
Reminder: First Quarter 2024 Financial Results Reporting and Conference Call on May 9, 2024 BOCA RATON, Fla, May 06, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces the sale of the first SRT-100 Vision™ (IG-SRT) system in Asia, to Far Eastern Memorial Hospital in Taiwan. The hospital, which has more than 1,000 beds, is one of the largest private hospitals in Taiwan. Far Eastern Memorial Hospital also plans to publish research on possible new indications for the SRT-100 Vision (IG-SRT), which may be instrumental in
Maxim Group reiterated coverage of Sensus Healthcare with a rating of Buy and set a new price target of $14.00 from $12.00 previously
HC Wainwright & Co. reiterated coverage of Sensus Healthcare with a rating of Buy and set a new price target of $13.00 from $12.00 previously
HC Wainwright & Co. reiterated coverage of Sensus Healthcare with a rating of Buy and set a new price target of $12.00 from $10.00 previously
HC Wainwright & Co. reiterated coverage of Sensus Healthcare with a rating of Buy and set a new price target of $10.00 from $9.00 previously
HC Wainwright & Co. reiterated coverage of Sensus Healthcare with a rating of Buy and set a new price target of $9.00 from $7.00 previously
HC Wainwright & Co. reiterated coverage of Sensus Healthcare with a rating of Buy and set a new price target of $7.00 from $6.00 previously
HC Wainwright reiterated coverage of Sensus Healthcare with a rating of Buy and set a new price target of $6.00 from $4.00 previously
Roth Capital reiterated coverage of Sensus Healthcare with a rating of Buy and set a new price target of $6.00 from $4.00 previously
HC Wainwright & Co. reiterated coverage of Sensus Healthcare with a rating of Buy and set a new price target of $6.00 from $4.00 previously
Roth Capital reiterated coverage of Sensus Healthcare with a rating of Buy and set a new price target of $6.00 from $4.00 previously
BOCA RATON, Fla., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that Samuel O'Rear will not stand for reelection to the Company's Board of Directors at the Company's 2024 annual meeting of stockholders. Mr. O'Rear has been a Director of Sensus Healthcare since 2012. As previously announced, on January 11, 2024 the Board of Directors of Sensus Healthcare appointed Michael J. Sardano, President and General Counsel of Sensus Healthcare, as a Director, effective today. "Sam has been inv
BOCA RATON, Fla, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces the following promotions, all effective immediately: Vice President and General Counsel Michael J. Sardano has been promoted to President and General CounselSales Manager Christopher Machuzak has been promoted to Vice President of Sales for the West CoastSoutheast Regional Sales Manager Jeffrey Starling has been promoted to Vice President of Sales for the East Coast In addition, the Company announces the retirement of Steve Cohen, Executive Vice Pre
BOCA RATON, Fla., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that it has entered into a new exclusive distribution agreement with Ekpac Healthcare Ltd. to market Sensus SRT-100™ systems in China and Hong Kong. This agreement is effective as of January 1, 2021. Sensus currently has 40 units installed throughout China in public and private hospitals as well as private clinics. It expects this relationship to accelerate SRT-100 unit population in the region. SRT-100 systems utilize S
SC 13G/A - Sensus Healthcare, Inc. (0001494891) (Subject)
SC 13G/A - Sensus Healthcare, Inc. (0001494891) (Subject)
SC 13G/A - Sensus Healthcare, Inc. (0001494891) (Subject)
SC 13G - Sensus Healthcare, Inc. (0001494891) (Subject)
4 - Sensus Healthcare, Inc. (0001494891) (Issuer)
4 - Sensus Healthcare, Inc. (0001494891) (Issuer)
4 - Sensus Healthcare, Inc. (0001494891) (Issuer)
4/A - Sensus Healthcare, Inc. (0001494891) (Issuer)
4/A - Sensus Healthcare, Inc. (0001494891) (Issuer)
4 - Sensus Healthcare, Inc. (0001494891) (Issuer)
4 - Sensus Healthcare, Inc. (0001494891) (Issuer)
4 - Sensus Healthcare, Inc. (0001494891) (Issuer)
4 - Sensus Healthcare, Inc. (0001494891) (Issuer)
4 - Sensus Healthcare, Inc. (0001494891) (Issuer)
This revised news release replaces the one issued on November 14, 2024, contains several non-financial changes throughout and removes the name of and references to a new customer, at the customer's request. The agreement with the new customer remains in effect. Revenues of $8.8 million compare with $3.9 million in the prior-year quarter, adjusted EBITDA (a non-GAAP measure) of $1.6 million compares with negative $1.7 million a year ago Expects to have more than 50 IG-SRT Systems signed under the Fair Deal Agreement recurring-revenue program by the end of the year BOCA RATON, Fla, Nov. 17, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializin
Revenues of $8.8 million compare with $3.9 million in the prior-year quarter, adjusted EBITDA (a non-GAAP measure) of $1.6 million compares with negative $1.7 million a year agoSigned a Fair Deal Agreement with Platinum Dermatology, a leading dermatology network with 130 clinics across the U.S. Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces financial results for the three and nine months ended September 30, 2
BOCA RATON, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, November 14, 2024 at 4:30 p.m. Eastern time to discuss the financial results for the third quarter of 2024. In addition, management will provide a business update and a discussion on recent and upcoming milestones. Participants are encouraged to pre-register for the conference call using this link. Upon registration participants will receive a unique dial-in number that will permit them to bypass
Revenues of $9.2 million compares with $4.5 million in the prior-year quarter, adjusted EBITDA (a non-GAAP measure) of $2.1 million compares with negative $1.0 million a year ago"Fair Deal Agreement" recurring revenue program gaining momentum with 15 agreements signed to date Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces financial results for the three and six months ended June 30, 2024. Highlights from the
BOCA RATON, Fla. , Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, reminds investors that management will hold a conference call on Thursday, August 8, 2024 at 4:30 p.m. Eastern time to discuss the financial results for the second quarter of 2024. In addition, management will provide a business update and a discussion on recent and upcoming milestones. Participants are encouraged to pre-register for the conference call using this link. Upon registration participants will receive a unique dial in number that will permit them to
BOCA RATON, Fla., July 25, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, August 8, 2024 at 4:30 p.m. Eastern time to discuss the financial results for the second quarter of 2024. In addition, management will provide a business update and a discussion on recent and upcoming milestones. Participants are encouraged to pre-register for the conference call using this link. Upon registration participants will receive a unique dial in number that will permit them to bypass the
Revenues of $10.7 million, compared with $3.4 million in the prior-year quarter; Adjusted EBITDA (a non-GAAP measure) of $3.0 million, compared with negative $2.7 million in the prior-year quarterLaunched the "Fair Deal Agreement" recurring revenue program to provide an equipment placement option and complement the fair market value lease program for SRT systems Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces financ
First veterinary commercial sale of the SRT-100 outside the U.S. BOCA RATON, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces the sale of an SRT-100 system to Chavat Da'at, the Veterinary Specialist Referral Center Knowledge Farm at Beit Verl College in Tel Aviv, to provide a gentler radiotherapy option to treat tumors in dogs and cats. This is the first commercial sale of the SRT-100 for veterinary use outside the U.S. Veterinary Specialist Referral Center Knowledge Farm was establ
Reminder: First Quarter 2024 Financial Results Reporting and Conference Call on May 9, 2024 BOCA RATON, Fla, May 06, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces the sale of the first SRT-100 Vision™ (IG-SRT) system in Asia, to Far Eastern Memorial Hospital in Taiwan. The hospital, which has more than 1,000 beds, is one of the largest private hospitals in Taiwan. Far Eastern Memorial Hospital also plans to publish research on possible new indications for the SRT-100 Vision (IG-SRT), which may be instrumental in
BOCA RATON, Fla., April 25, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, reminds investors that management will hold a conference call on Thursday, May 9, 2024 at 4:30 p.m. Eastern time to discuss the financial results for the first quarter of 2024. In addition, management will provide a business update and a discussion on recent and upcoming milestones. Participants are encouraged to pre-register for the conference call using this link. Upon registration participants will receive a unique dial in number that will permit them to
8-K - Sensus Healthcare, Inc. (0001494891) (Filer)
10-Q - Sensus Healthcare, Inc. (0001494891) (Filer)
8-K - Sensus Healthcare, Inc. (0001494891) (Filer)
8-K - Sensus Healthcare, Inc. (0001494891) (Filer)
10-Q - Sensus Healthcare, Inc. (0001494891) (Filer)
8-K - Sensus Healthcare, Inc. (0001494891) (Filer)
8-K - Sensus Healthcare, Inc. (0001494891) (Filer)
8-K - Sensus Healthcare, Inc. (0001494891) (Filer)
SD - Sensus Healthcare, Inc. (0001494891) (Filer)
10-Q - Sensus Healthcare, Inc. (0001494891) (Filer)
HC Wainwright & Co. analyst Yi Chen maintains Sensus Healthcare (NASDAQ:SRTS) with a Buy and raises the price target from $8 to $10.
Shares of Diodes Incorporated (NASDAQ:DIOD) fell sharply during Friday's session after the company reported worse-than-expected quarterly financial results. Diodes posted adjusted earnings of 28 cents per share, missing market estimates of 31 cents per share. The company's quarterly sales came in at $301.97 million missing expectations of $305.01 million, according to data from Benzinga Pro. Diodes shares dipped 9.8% to $68.99 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Novavax, Inc. (NASDAQ:NVAX) shares jumped 139% to $10.73 after the company and Sanofi announced a co-exclusive licensing agreement to commercialize a COVID-19 vaccine and d
Gainers Novavax (NASDAQ:NVAX) stock increased by 110.7% to $9.42 during Friday's regular session. The market value of their outstanding shares is at $1.3 billion. The company's, Q1 earnings came out today. Portage Biotech (NASDAQ:PRTG) stock increased by 57.97% to $0.41. The market value of their outstanding shares is at $8.1 million. ITeos Therapeutics (NASDAQ:ITOS) stock rose 46.92% to $17.91. The company's market cap stands at $644.1 million. As per the press release, Q1 earnings came out today. Sensus Healthcare (NASDAQ:SRTS) stock moved upwards by 37.87% to $5.25. The company's market cap stands at $86.1 million. As per the press release, Q1 earnings came out yesterday. Cardio Diag
Maxim Group analyst Anthony Vendetti maintains Sensus Healthcare (NASDAQ:SRTS) with a Buy and raises the price target from $7 to $10.
Shares of Natera, Inc. (NASDAQ:NTRA) rose sharply in today's pre-market trading following strong first-quarter earnings. Natera posted GAAP loss of 56 cents per share, compared to market expectations for a loss of 71 cents per share. The company's quarterly sales came in at $367.700 million versus estimates of $316.306 million. Natera, shares jumped 15.3% to $110.25 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Novavax, Inc. (NASDAQ:NVAX) gained 165% to $11.84 in pre-market trading after the company reported first-quarter results. AEye, Inc. (NASDAQ:LIDR) gained 38.1% to $1.63 in pre-market trading after the company disclosed a par
Gainers Aethlon Medical (NASDAQ:AEMD) stock moved upwards by 129.0% to $2.7 during Friday's pre-market session. The company's market cap stands at $7.1 million. Novavax (NASDAQ:NVAX) shares rose 119.23% to $9.8. The market value of their outstanding shares is at $1.3 billion. The company's, Q1 earnings came out today. Sensus Healthcare (NASDAQ:SRTS) stock moved upwards by 51.18% to $5.76. The company's market cap stands at $94.4 million. As per the news, the Q1 earnings report came out yesterday. Natera (NASDAQ:NTRA) shares moved upwards by 20.31% to $114.96. The market value of their outstanding shares is at $14.0 billion. The company's, Q1 earnings came out yesterday. XTL Biopharmaceu
Sensus Healthcare (NASDAQ:SRTS) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of $(0.06) by 333.33 percent. This is a 216.67 percent increase over losses of $(0.12) per share from the same period last year. The company reported quarterly sales of $10.663 million which beat the analyst consensus estimate of $4.120 million by 158.81 percent. This is a 212.33 percent increase over sales of $3.414 million the same period last year.
Gainers Sensus Healthcare (NASDAQ:SRTS) shares increased by 33.3% to $5.08 during Thursday's after-market session. The market value of their outstanding shares is at $83.2 million. As per the news, the Q1 earnings report came out today. TELA Bio (NASDAQ:TELA) shares moved upwards by 13.36% to $5.6. The company's market cap stands at $138.0 million. As per the press release, Q1 earnings came out today. CareDx (NASDAQ:CDNA) stock increased by 13.01% to $12.5. The company's market cap stands at $650.1 million. The company's, Q1 earnings came out today. Natera (NASDAQ:NTRA) stock moved upwards by 12.42% to $107.5. The market value of their outstanding shares is at $13.1 billion. As per the p